Evidence map›Paper›PMID 41493720›Full record

ArticleInternational journal of hematology2026

Prognostic factors influencing outcomes of allogeneic HCT for AML with monosomal karyotype.

Hiroki Yokoyama, Masamitsu Yanada, Shohei Mizuno, Naoyuki Uchida, Naoki Shingai, Takahiro Fukuda, Masatsugu Tanaka, Satoshi Yoshihara, Tetsuya Nishida, Masashi Sawa and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hiroki YokoyamaDivision of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan. hiroki52@jikei.ac.jp.ORCID http://orcid.org/0009-0002-6712-9012
Masamitsu YanadaDepartment of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.
Shohei MizunoDivision of Hematology, Department of Internal Medicine, Aichi Medical University, Nagakute, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Naoki ShingaiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Hyogo, Japan.
Tetsuya NishidaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Satoru TakadaLeukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan.
Toshiro KawakitaDepartment of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaDepartment of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.
Shingo YanoDivision of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishishinbashi, Minato-ku, Tokyo, 105-8461, Japan.
for Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monosomal karyotype (MK) comprises chromosomal abnormalities defined as either one single autosomal monosomy with structural abnormalities (MK1) or two or more distinct autosomal monosomies (MK2). MK is a predictive factor for extremely poor prognosis in patients with acute myeloid leukemia (AML), and not all patients are eligible for allogeneic hematopoietic cell transplantation (HCT). Using registry data from the Japan Society for Transplantation and Cellular Therapy, we retrospectively analyzed 892 AML patients with MK who underwent initial HCT between 2000 and 2017. The median follow-up among surviving patients was 3.1 years (range, 0.1-13.8 years). The 3-year overall survival (OS) rate was 26% for the 284 MK1 patients, which was significantly higher than the 10% observed in the 608 MK2 patients (P < 0.001). Multivariate analysis showed that MK subtype, disease status at time of HCT, patient age at HCT, sex, performance status, and year of HCT significantly affected OS. Notably, MK1 was associated with better OS than MK2 in both patients in complete remission (CR) and non-CR patients. Molecular pathogenesis may be different between MK1 and MK2, and further investigation is required to gain biological insight into the impact of MK subtype on post-HCT outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMonosomyAdolescentAdultAgedAllograftsChildFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateTransplantation, HomologousAcute myeloid leukemiaAllogeneic hematopoietic cell transplantationMonosomal karyotype

Identifiers

PMID41493720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.